Luke Sergott
Stock Analyst at Barclays
(2.30)
# 1,409
Out of 4,412 analysts
170
Total ratings
43.42%
Success rate
-4.59%
Average return
Main Sectors:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher | Maintains: Equal-Weight | $590 → $615 | $576.89 | +6.61% | 20 | Apr 25, 2024 | |
| DHR Danaher | Maintains: Equal-Weight | $260 → $270 | $246.82 | +9.39% | 18 | Apr 24, 2024 | |
| TXG 10x Genomics | Maintains: Overweight | $55 → $45 | $28.40 | +58.45% | 5 | Apr 10, 2024 | |
| A Agilent Technologies | Maintains: Underweight | $125 → $135 | $139.59 | -3.29% | 1 | Apr 10, 2024 | |
| AVTR Avantor | Maintains: Overweight | $27 → $30 | $24.08 | +24.58% | 17 | Apr 10, 2024 | |
| ILMN Illumina | Maintains: Underweight | $85 → $100 | $124.73 | -19.83% | 11 | Apr 10, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Equal-Weight | $8 → $3 | $1.60 | +87.50% | 3 | Apr 10, 2024 | |
| SHC Sotera Health Company | Maintains: Overweight | $19 → $14 | $11.38 | +23.02% | 14 | Apr 10, 2024 | |
| TWST Twist Bioscience | Maintains: Overweight | $45 → $40 | $32.03 | +24.88% | 12 | Apr 10, 2024 | |
| ICLR ICON PLC | Maintains: Overweight | $325 → $355 | $304.14 | +16.72% | 12 | Feb 23, 2024 | |
| IQV IQVIA Holdings | Maintains: Overweight | $260 → $265 | $235.48 | +12.54% | 14 | Feb 15, 2024 | |
| WAT Waters | Maintains: Underweight | $275 → $300 | $315.09 | -4.79% | 11 | Feb 12, 2024 | |
| RVTY Revvity | Maintains: Equal-Weight | $92 → $105 | $105.02 | -0.02% | 3 | Jan 25, 2024 | |
| FTRE Fortrea Holdings | Maintains: Overweight | $38 → $35 | $37.54 | -6.77% | 3 | Jan 25, 2024 | |
| CERT Certara | Maintains: Equal-Weight | $16 → $18 | $17.08 | +5.39% | 10 | Jan 25, 2024 | |
| CTLT Catalent | Maintains: Equal-Weight | $45 → $47 | $56.30 | -16.52% | 15 | Jan 25, 2024 | |
| CNTG Centogene | Downgrades: In-Line | n/a | $0.46 | - | 1 | Apr 24, 2020 |
Thermo Fisher
Apr 25, 2024
Maintains: Equal-Weight
Price Target: $590 → $615
Current: $576.89
Upside: +6.61%
Danaher
Apr 24, 2024
Maintains: Equal-Weight
Price Target: $260 → $270
Current: $246.82
Upside: +9.39%
10x Genomics
Apr 10, 2024
Maintains: Overweight
Price Target: $55 → $45
Current: $28.40
Upside: +58.45%
Agilent Technologies
Apr 10, 2024
Maintains: Underweight
Price Target: $125 → $135
Current: $139.59
Upside: -3.29%
Avantor
Apr 10, 2024
Maintains: Overweight
Price Target: $27 → $30
Current: $24.08
Upside: +24.58%
Illumina
Apr 10, 2024
Maintains: Underweight
Price Target: $85 → $100
Current: $124.73
Upside: -19.83%
Pacific Biosciences of California
Apr 10, 2024
Maintains: Equal-Weight
Price Target: $8 → $3
Current: $1.60
Upside: +87.50%
Sotera Health Company
Apr 10, 2024
Maintains: Overweight
Price Target: $19 → $14
Current: $11.38
Upside: +23.02%
Twist Bioscience
Apr 10, 2024
Maintains: Overweight
Price Target: $45 → $40
Current: $32.03
Upside: +24.88%
ICON PLC
Feb 23, 2024
Maintains: Overweight
Price Target: $325 → $355
Current: $304.14
Upside: +16.72%
IQVIA Holdings
Feb 15, 2024
Maintains: Overweight
Price Target: $260 → $265
Current: $235.48
Upside: +12.54%
Waters
Feb 12, 2024
Maintains: Underweight
Price Target: $275 → $300
Current: $315.09
Upside: -4.79%
Revvity
Jan 25, 2024
Maintains: Equal-Weight
Price Target: $92 → $105
Current: $105.02
Upside: -0.02%
Fortrea Holdings
Jan 25, 2024
Maintains: Overweight
Price Target: $38 → $35
Current: $37.54
Upside: -6.77%
Certara
Jan 25, 2024
Maintains: Equal-Weight
Price Target: $16 → $18
Current: $17.08
Upside: +5.39%
Catalent
Jan 25, 2024
Maintains: Equal-Weight
Price Target: $45 → $47
Current: $56.30
Upside: -16.52%
Centogene
Apr 24, 2020
Downgrades: In-Line
Price Target: n/a
Current: $0.46
Upside: -